Hormonal
Elevated circulating asprosin levels are positively associated with insulin resistance, type 2 diabetes, and obesity in adult populations, suggesting asprosin acts as a biomarker for metabolic dysregulation.
If you have insulin resistance or type 2 diabetes, your body may be producing higher levels of the hormone asprosin, which is linked to your condition. While this doesn't change your immediate treatment, it highlights the importance of managing blood sugar and weight, as lower asprosin levels are associated with better metabolic health. Future treatments may target this hormone.
It has been reported that increased plasma asprosin levels can be observed in human subjects and mice with IR... The study demonstrated that higher plasma asprosin was found in IGR and nT2DM groups in comparison with the NGR group... Asprosin was positively associated with the homeostasis model assessment for IR (HOMA-IR)
Why this rating
Based on multiple cross-sectional and case-control human studies, but causality is explicitly noted as unestablished.
Source
Asprosin: A Novel Player in Metabolic Diseases
Mingyang Yuan et al. · Frontiers in Endocrinology · 2020
DOI 10.3389/fendo.2020.00064
More from this paper
- Asprosin promotes hepatic glucose production (gluconeogenesis) and stimulates appetite (orexigenic effect) via central and peripheral signaling pathways, although the reproducibility of these effects is controversial due to reagent quality issues.Limited
- Asprosin may have a protective role in cardiovascular disease by preventing cardiomyocyte apoptosis and improving mesenchymal stromal cell function in myocardial infarction models.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →